MANE
Veradermics, Inc
$96.07
+1.77%
$4.0B
No data for this timeframe.
Vol
Market Cap$4.0B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders36 funds
Inst. Value$628.0M
Inst. Activity10 buys / 0 sells
Insider Activity8B / 0S
Insider Net $$18.4M
Reddit Sentiment33° Cool
SEC Reports4
Recent Activity
May 29, 2026
short_volume
Short Volume: MANE — 69.4% short (0.4M / 0.5M)
Short: 372,407 | Exempt: 321 | TRF Vol: 536,958 | Short Ratio: 69.4% | Off-exchange volume (dark poo
May 12, 2026
SEC
Veradermics reported Q1 2026 results showing a net loss of $27.2M, widening from a $12.4M loss in Q1 2025, driven by inc
8-K — Impact 5/10
May 1, 2026
SEC
Veradermics closed an underwritten public offering of 3,843,790 shares at $100.00 per share, raising ~$384M, and a concu
8-K — Impact 5/10
May 1, 2026
Insider
SUVRETTA CAPITAL MANAGEMENT, LLC was granted 149,000 shares
Director @ $100.00 ($14.9M)
Apr 27, 2026
SEC
Veradermics reports preliminary Q1 2026 cash of $390.8M, up from $141.9M at year-end 2025, reflecting the February 2026
8-K — Impact 3/10
Feb 6, 2026
Insider
SUVRETTA CAPITAL MANAGEMENT, LLC bought 11,183 shares
Director @ $35.97 ($402.3K)
Feb 5, 2026
Insider
CHILDS JOHN W bought 294,117 shares
Director @ $17.00 ($5.0M)
Inst.
FMR LLC — NEW
1,792,909 shares ($113.2M)
Price Targets
$132.25
+37.7% upside
Strong Buy
Current $96.07
Low $120.00
Median $135.50
High $138.00
4 analysts
$120.00
$138.00
Analyst Ratings
5Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | Needham | INITIATE | Buy |
| May 18, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Apr 22, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
| Mar 2, 2026 | Cantor Fitzgerald | INITIATE | Overweight |
| Mar 2, 2026 | Citigroup | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.66 ▲ +10.6% | $-0.71 — $-0.64 | 3 | |
| Next Q | $-0.65 ▼ -0.9% | $-0.77 — $-0.51 | 3 | |
| Current FY | $-3.05 ▼ -17.5% | $-3.35 — $-2.61 | 97% YoY | 3 |
| Next FY | $-3.04 ▼ -1.2% | $-3.54 — $-2.69 | 0% YoY | 3 |
Latest Reports
NEUTRAL
8-K
5/10
Veradermics reported Q1 2026 results showing a net loss of $27.2M, widening from a $12.4M loss in Q1 2025, driven by inc
May 12, 2026
NEUTRAL
8-K
5/10
Veradermics closed an underwritten public offering of 3,843,790 shares at $100.00 per share, raising ~$384M, and a concu
May 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| CITADEL ADVISORS LLC | $115.3M | — |
| FMR LLC | $113.2M | NEW |
| ADAGE CAPITAL PARTNERS GP, | $69.5M | NEW |
| VANGUARD CAPITAL MANAGEMENT LLC | $44.2M | — |
| MARSHALL WACE, LLP | $41.3M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | SUVRETTA CAPITAL | A | $14.9M |
| Feb 6, 2026 | SUVRETTA CAPITAL | BUY | $402.3K |
| Feb 5, 2026 | CHILDS JOHN | BUY | $5.0M |
| Feb 5, 2026 | SUVRETTA CAPITAL | BUY | $138.2K |
| Feb 5, 2026 | CHILDS JOHN | C | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
36 institutional holders with $628.0M total value (9,944,259 shares) as of 2026-Q1. Top holders: CITADEL, FMR, ADAGE. Net buying activity: 10 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 1,825,672 | $115.3M | 18.4% | — |
| 2 | FMR LLC | 1,792,909 | $113.2M | 18.0% | NEW |
| 3 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,100,000 | $69.5M | 11.1% | NEW |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 699,645 | $44.2M | 7.0% | — |
| 5 | MARSHALL WACE, LLP | 654,601 | $41.3M | 6.6% | NEW |
| 6 | BALYASNY ASSET MANAGEMENT L.P. | 532,906 | $33.7M | 5.4% | NEW |
| 7 | AMERIPRISE FINANCIAL INC | 514,035 | $32.5M | 5.2% | NEW |
| 8 | Woodline Partners LP | 500,646 | $31.6M | 5.0% | NEW |
| 9 | WELLINGTON MANAGEMENT GROUP LLP | 477,833 | $30.2M | 4.8% | NEW |
| 10 | STIFEL FINANCIAL CORP | 294,117 | $18.6M | 3.0% | NEW |
| 11 | BlackRock, Inc. | 282,611 | $17.8M | 2.8% | NEW |
| 12 | FRANKLIN RESOURCES INC | 200,000 | $12.6M | 2.0% | NEW |
| 13 | GOLDMAN SACHS GROUP INC | 168,975 | $10.7M | 1.7% | — |
| 14 | JENNISON ASSOCIATES LLC | 141,781 | $9.0M | 1.4% | — |
| 15 | D. E. Shaw & Co., Inc. | 134,219 | $8.5M | 1.3% | — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 98,009 | $6.2M | 1.0% | — |
| 17 | VANGUARD FIDUCIARY TRUST CO | 97,985 | $6.2M | 1.0% | — |
| 18 | STATE STREET CORP | 74,400 | $4.7M | 0.7% | — |
| 19 | BANK OF AMERICA CORP /DE/ | 65,675 | $4.1M | 0.7% | — |
| 20 | BAMCO INC /NY/ | 59,668 | $3.8M | 0.6% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | NEW | — | 1,792,909 | — | $113.2M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | — | 1,100,000 | — | $69.5M | 2026-Q1 |
| MARSHALL WACE, LLP | NEW | — | 654,601 | — | $41.3M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | NEW | — | 532,906 | — | $33.7M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | NEW | — | 514,035 | — | $32.5M | 2026-Q1 |
| Woodline Partners LP | NEW | — | 500,646 | — | $31.6M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | NEW | — | 477,833 | — | $30.2M | 2026-Q1 |
| STIFEL FINANCIAL CORP | NEW | — | 294,117 | — | $18.6M | 2026-Q1 |
| BlackRock, Inc. | NEW | — | 282,611 | — | $17.8M | 2026-Q1 |
| FRANKLIN RESOURCES INC | NEW | — | 200,000 | — | $12.6M | 2026-Q1 |
13 unique insiders with 40 transactions. Net insider value: $18.4M ($18.4M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | SUVRETTA CAPITAL MANAGEMENT, LLC | Director | AWARD | 149,000 | $100.00 | $14.9M |
| Feb 6, 2026 | SUVRETTA CAPITAL MANAGEMENT, LLC | Director | BUY | 11,183 | $35.97 | $402.3K |
| Feb 5, 2026 | CHILDS JOHN W | Director | BUY | 294,117 | $17.00 | $5.0M |
| Feb 5, 2026 | SUVRETTA CAPITAL MANAGEMENT, LLC | Director | BUY | 3,832 | $36.07 | $138.2K |
| Feb 5, 2026 | CHILDS JOHN W | Director | CONVERT | 480,269 | — | — |
| Feb 5, 2026 | CHILDS JOHN W | Director | BUY | 294,117 | $17.00 | $5.0M |
| Feb 5, 2026 | CHILDS JOHN W | Director | CONVERT | 480,269 | — | — |
| Feb 5, 2026 | CHILDS JOHN W | Director | CONVERT | 906,862 | — | — |
| Feb 5, 2026 | CHILDS JOHN W | Director | CONVERT | 520,758 | — | — |
| Feb 5, 2026 | Durso Timothy August | Chief Technical Officer | CONVERT | 1,473 | — | — |
| Feb 5, 2026 | Durso Timothy August | Chief Technical Officer | CONVERT | 1,473 | — | — |
| Feb 5, 2026 | Longitude Capital Partners V, LLC | 10%+ Owner | CONVERT | 1,236,631 | — | — |
| Feb 5, 2026 | Longitude Capital Partners V, LLC | 10%+ Owner | BUY | 192,647 | $17.00 | $3.3M |
| Feb 5, 2026 | Longitude Capital Partners V, LLC | 10%+ Owner | CONVERT | 1,236,631 | — | — |
| Feb 5, 2026 | Longitude Capital Partners V, LLC | 10%+ Owner | CONVERT | 1,171,121 | — | — |
| Feb 5, 2026 | Grant-Kels Jane M. | Director | CONVERT | 2,455 | — | — |
| Feb 5, 2026 | Grant-Kels Jane M. | Director | CONVERT | 2,455 | — | — |
| Feb 5, 2026 | Coric Vlad | Director | CONVERT | 33,706 | — | — |
| Feb 5, 2026 | Coric Vlad | Director | BUY | 58,823 | $17.00 | $1000.0K |
| Feb 5, 2026 | ENRIGHT PATRICK G | Director | BUY | 192,647 | $17.00 | $3.3M |
| Feb 5, 2026 | Coric Vlad | Director | CONVERT | 33,706 | — | — |
| Feb 5, 2026 | Coric Vlad | Director | CONVERT | 148,794 | — | — |
| Feb 5, 2026 | Coric Vlad | Director | CONVERT | 78,075 | — | — |
| Feb 5, 2026 | ENRIGHT PATRICK G | Director | CONVERT | 1,236,631 | — | — |
| Feb 5, 2026 | ENRIGHT PATRICK G | Director | CONVERT | 1,236,631 | — | — |
| Feb 5, 2026 | ENRIGHT PATRICK G | Director | CONVERT | 1,171,121 | — | — |
| Feb 5, 2026 | Waldman Reid Alexander | Chief Executive Officer | CONVERT | 1,437 | — | — |
| Feb 5, 2026 | Waldman Reid Alexander | Chief Executive Officer | CONVERT | 1,437 | — | — |
| Feb 4, 2026 | SUVRETTA CAPITAL MANAGEMENT, LLC | Director | BUY | 10,004 | $34.25 | $342.6K |
| Feb 3, 2026 | CHILDS JOHN W | Director | AWARD | 51,525 | — | — |
| Feb 3, 2026 | Durso Timothy August | Chief Technical Officer | AWARD | 213,352 | — | — |
| Feb 3, 2026 | Grant-Kels Jane M. | Director | AWARD | 51,525 | — | — |
| Feb 3, 2026 | Friedman David Matthew | Director | AWARD | 43,000 | — | — |
| Feb 3, 2026 | Coric Vlad | Director | AWARD | 51,525 | — | — |
| Feb 3, 2026 | ENRIGHT PATRICK G | Director | AWARD | 45,131 | — | — |
| Feb 3, 2026 | Greco Michael V. | General Counsel | AWARD | 144,401 | — | — |
| Feb 3, 2026 | Waldman Reid Alexander | Chief Executive Officer | AWARD | 556,399 | — | — |
| Feb 3, 2026 | Neumann Mark | Chief Commercial Officer | AWARD | 102,885 | — | — |
| Feb 3, 2026 | Carrano Dominic Gabriel | Chief Financial Officer | AWARD | 148,011 | — | — |
| Feb 3, 2026 | Pance Katarina | Director | AWARD | 43,000 | — | — |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 5.0/10.
NEUTRAL
8-K
5/10
Veradermics reported Q1 2026 results showing a net loss of $27.2M, widening from a $12.4M loss in Q1
May 12, 2026
NEUTRAL
8-K
5/10
Veradermics closed an underwritten public offering of 3,843,790 shares at $100.00 per share, raising
May 1, 2026
NEUTRAL
8-K
3/10
Veradermics reports preliminary Q1 2026 cash of $390.8M, up from $141.9M at year-end 2025, reflectin
Apr 27, 2026
BULLISH
8-K
7/10
Veradermics announced positive topline results from its Phase 2/3 Study 302 evaluating VDPHL01, an o
Apr 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 5 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$132.25 mean target
+37.7% upside
Strong Buy (1.20)
$120.00 Low
$138.00 High
| Metric | Value |
|---|---|
| Current Price | $96.07 |
| Target Low | $120.00 |
| Target Mean | $132.25 |
| Target Median | $135.50 |
| Target High | $138.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.20) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.66 | $-0.71 | $-0.64 | — | +10.6% | 1↑ 0↓ | $0.0B | — | 3 |
| Next Q 2026-09-30 |
$-0.65 | $-0.77 | $-0.51 | — | -0.9% | 1↑ 0↓ | $0.0B | — | 3 |
| Current FY 2026-12-31 |
$-3.05 | $-3.35 | $-2.61 | 97.3% | -17.5% | 0↑ 1↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-3.04 | $-3.54 | $-2.69 | 0.4% | -1.2% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.662 | |
| 7d ago | $-0.673 | +0.011 |
| 30d ago | $-0.740 | +0.078 |
| 60d ago | $-0.740 | +0.078 |
| 90d ago | $-3.029 | +2.368 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 5 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | Needham | INITIATE | — | Buy |
| May 18, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Apr 22, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Mar 2, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Mar 2, 2026 | Citigroup | INITIATE | — | Buy |
| Mar 2, 2026 | Leerink Partners | INITIATE | — | Outperform |
| Mar 2, 2026 | Jefferies | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 4 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 5 | 4 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 5 | 4 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
May 29, 2026
short_volume
Short Volume: MANE — 69.4% short (0.4M / 0.5M)
Short: 372,407 | Exempt: 321 | TRF Vol: 536,958 | Short Ratio: 69.4% | Off-exchange volume (dark pool + OTC)
May 19, 2026
Clinical Trial
Safety and Efficacy of VDPHL01 in Males and Females With AGA
Phase Phase 2 — ACTIVE_NOT_RECRUITING
May 19, 2026
clinical_trial_readout
T-90d Trial Readout: VDPHL01 (Phase 2)
Trial: Safety and Efficacy of VDPHL01 in Males and Females With AGA
Sponsor: Veradermics, Inc.
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Conditio
May 14, 2026
clinical_trial_readout
T-90d Trial Readout: VDPHL01 (Phase 2)
Trial: Safety and Efficacy of VDPHL01 in Males and Females With AGA
Sponsor: Veradermics, Inc.
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Conditio
May 5, 2026
short_volume
Short Volume: MANE — 62.2% short (0.4M / 0.6M)
Short: 366,975 | Exempt: 0 | TRF Vol: 589,994 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_interest
FTD: MANE — 17,658 shares ($1.9M) failed to deliver
Settlement: 20260505, Price: $105.26, FTD Value: $1,858,681.08, VERADERMICS INC COM
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: VDPHL01 (Phase 2)
Trial: Safety and Efficacy of VDPHL01 in Males and Females With AGA
Sponsor: Veradermics, Inc.
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Conditio
May 4, 2026
short_interest
FTD: MANE — 4,955 shares ($0.5M) failed to deliver
Settlement: 20260504, Price: $101.00, FTD Value: $500,455, VERADERMICS INC COM
May 3, 2026
clinical_trial_readout
T-90d Trial Readout: VDPHL01 (Phase 2)
Trial: Safety and Efficacy of VDPHL01 in Males and Females With AGA
Sponsor: Veradermics, Inc.
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Conditio
May 1, 2026
short_interest
FTD: MANE — 9,504 shares ($0.9M) failed to deliver
Settlement: 20260501, Price: $99.00, FTD Value: $940,896, VERADERMICS INC COM
Apr 30, 2026
short_volume
Short Volume: MANE — 67.1% short (0.5M / 0.7M)
Short: 463,020 | Exempt: 0 | TRF Vol: 690,213 | Short Ratio: 67.1% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: MANE — 60.9% short (0.4M / 0.6M)
Short: 369,312 | Exempt: 64 | TRF Vol: 605,963 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)
Apr 9, 2026
short_interest
FTD: MANE — 17,254 shares ($1.0M) failed to deliver
Settlement: 20260409, Price: $58.04, FTD Value: $1,001,422.16, VERADERMICS INC COM
Apr 1, 2026
short_interest
FTD: MANE — 13,031 shares ($0.8M) failed to deliver
Settlement: 20260401, Price: $63.15, FTD Value: $822,907.65, VERADERMICS INC COM
Mar 31, 2026
short_interest
FTD: MANE — 8,976 shares ($0.5M) failed to deliver
Settlement: 20260331, Price: $60.85, FTD Value: $546,189.6, VERADERMICS INC COM
Mar 20, 2026
short_interest
FTD: MANE — 14,050 shares ($0.8M) failed to deliver
Settlement: 20260320, Price: $56.91, FTD Value: $799,585.5, VERADERMICS INC COM